If you have been reading about half-life and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-08. Numbers and descriptions here follow the published literature rather than marketing material.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
== Applications == All chromatographic purifications and separations which are executed via solvent gradient batch chromatography can be performed using MCSGP. Typical examples are reversed phase purification of peptides, hydrophobic interaction chromatography for fatty acids or for example ion exchange chromatography of proteins or antibodies. The process can effectively enrich components, which have been fed in only small amounts. Continuous capturing of antibodies without affinity chromatography can be realized with the MCSGP-process.
In 1983 Stuart Beal (and also independently Santiago Schnell and Claudio Mendoza in 1997) derived a closed form solution for the time course kinetics analysis of the Michaelis-Menten mechanism. The solution, known as the Schnell-Mendoza equation, has the form:
== Election to Kerala Legislative Assembly == Anoop's father, who was the Minister for Food and Civil Supplies, died on 30 October 2011. Following this, Anoop was nominated by the Kerala Congress (Jacob) and UDF to contest from the Piravom assembly seat previously represented by his father. His father had lost the sitting seat in 2006 elections and recaptured it in 2011 election by a margin of 157 votes. Against Anoop Jacob, CPI(M)–led LDF once again fielded M. J. Jacob, who had won against T. M. Jacob in 2006 and lost in 2011. Since the result of Piravom by-election mattered heavily to the ruling UDF who had a slender margin of 1 seat in the Legislative assembly over LDF, the constituency witnessed intense campaigning from both sides. Election was held on 17 March 2012 and results were announced on 21 March 2012. Anoop Jacob won the by-election by a significant margin of 12,071 votes. He was sworn in as an MLA on 22 March 2012. Anoop took oath as the Minister for Food & Civil Supplies on 12 April 2012 and occupied office in the North Block of the Kerala Secretariat; both portfolio & office last held by his departed father.
=== Pharmacodynamics === Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors and selectivity over the non-human MT3 receptor. Ramelteon demonstrates full agonist activity in vitro in cells expressing human MT1 or MT2 receptors, and high selectivity for human MT1 and MT2 receptors compared to the non-human MT3 receptor. The affinity of ramelteon for the MT1 and MT2 receptors is 3 to 16 times higher than that of melatonin. Ramelteon has 8-fold higher affinity for the MT1 receptor over the MT2 receptor. The binding profile of ramelteon distinguishes it from melatonin, tasimelteon, and agomelatine. Remelteon has a clinically irrelevant affinity for the serotonin 5-HT1A receptor (Ki = 5.6 μM). The major metabolite of ramelteon, M-II, is active and has approximately one-tenth and one-fifth the binding affinity of the parent molecule for the human MT1 and MT2 receptors, respectively, and is 17- to 25-fold less potent than ramelteon in in vitro functional assays. Although the potency of M-II at MT1 and MT2 receptors is lower than the parent drug, M-II circulates at higher concentrations than the parent producing 20- to 100-fold greater mean systemic exposure when compared to ramelteon. M-II has weak affinity for the serotonin 5-HT2B receptor, but no appreciable affinity for other receptors or enzymes. Similar to ramelteon, M-II does not interfere with the activity of a number of endogenous enzymes.
An alternative method for removal of caffeine from coffee is the Swiss Water process. This process uses no organic solvents, and instead only water is used to decaffeinate beans. It is a technique first developed in Switzerland in 1933, and commercialized by Coffex S.A. in 1980. The Swiss Water process was then introduced by The Swiss Water Decaffeinated Coffee Company of Burnaby, British Columbia, in 1988. The process uses green coffee extract (GCE) for the caffeine extraction mechanism. Green coffee extract is a solution containing the water-soluble components of green coffee except for the caffeine, obtained by soaking green coffee beans in hot water, then filtering through an activated charcoal filter to remove the caffeine molecules. Fresh beans containing both caffeine and the other components are added to the GCE solution, where the gradient pressure difference between the GCE (which is caffeine-lean) and the green coffee (which is caffeine-rich) causes the caffeine molecules to migrate from the green coffee into the GCE. Because GCE is saturated with the other water-soluble components of green coffee, only the caffeine molecules migrate to the GCE; the other water-soluble coffee elements are retained in the green coffee. The newly caffeine-rich GCE solution is then passed through the activated carbon filters to remove the caffeine again, and the process is repeated. The continuous batch process takes 8–10 hours to meet the final residual decaffeinated target. Food engineer Torunn Atteraas Garin also developed a process to remove caffeine from coffee.
Sources: en.wikipedia.org
=== Physical examination === During a physical examination to check for MG, a doctor might ask the person to perform repetitive movements. For instance, the doctor may ask one to look at a fixed point for 30 seconds and to relax the muscles of the forehead, because a person with MG and ptosis of the eyes might be involuntarily using the forehead muscles to compensate for the weakness in the eyelids. The clinical examiner might also try to elicit the "curtain sign" in a person by holding one of the person's eyes open, which in the case of MG will lead the other eye to close.
1993/354) Council Tax (Alteration of Lists and Appeals) (Scotland) Regulations 1993 (S.I. 1993/355) Poultry Laying Flocks (Testing and Registration etc.) (Revocation) Order 1993 (S.I. 1993/357) A249 Trunk Road (M2 to Bobbing Improvement) Order 1993 (S.I. 1993/360) A249 Trunk Road (M2 to Bobbing Improvement Slip Roads) Order 1993 (S.I. 1993/361) A249 Trunk Road (M2 to Bobbing Improvement Detrunking) Order 1993 (S.I. 1993/362) M66 Motorway (Manchester Outer Ring Road, Denton to Middleton Section) A663 Broadway All-Purpose Connecting Road Order 1993 (S.I. 1993/363) M66 Motorway (Manchester Outer Ring Road, Denton to Middleton Section) and Connecting Roads Scheme 1988 Amendment Scheme 1993 (S.I. 1993/364) Local Government Act 1988 (Defined Activities) (Exemption) (Greater Manchester Fire and Civil Defence Authority) Order 1993 (S.I. 1993/365) Local Government Superannuation (Amendment) Regulations 1993 (S.I. 1993/366) Probation (Amendment) Rules 1993 (S.I. 1993/367) Criminal Justice Act 1991 (Contracted Out Prisons) Order 1993 (S.I. 1993/368) Scottish Hospital Trust Scheme 1993 (S.I. 1993/372) Registration of Births, Deaths and Marriages (Fees) (Amendment) Order 1993 (S.I. 1993/377) Cheshire, Lancashire and Merseyside (County Boundaries) Order 1993 (S.I. 1993/378) Norfolk and Suffolk Broads (Extension of Byelaws) Order 1993 (S.I. 1993/379) Defence Research Agency Trading Fund Order 1993 (S.I. 1993/380) Sea Fishing (Enforcement of Community Quota Measures) Order 1993 (S.I. 1993/387) Derbyshire and South Yorkshire (County and District Boundaries) Order 1993 (S.I.
Potassium alum was the major immunologic adjuvant used to increase the efficacy of vaccines, and has been used since the 1920s. But it has been almost completely replaced by aluminium hydroxide and aluminium phosphate in commercial vaccines. Alum may be used in depilatory waxes used for the removal of body hair or applied to freshly waxed skin as a soothing agent.
=== Role in coagulation === Limulus clotting enzyme is part of the coagulation cascade in horseshoe crab hemocytes. The cascade is triggered by the presence of bacterial endotoxins, which are detected by Limulus clotting factor C. Factor C activates factor B, which activates the clotting enzyme. The clotting enzyme then activates coagulin. The coagulation cascade can also be triggered by (1,3)-β-D-glucan, a constituent of many fungal cell walls. The (1,3)-β-D-glucan-mediated cascade follows a different pathway than the endotoxin-mediated cascade. When (1,3)-β-D-glucan is present, Limulus factor G is activated. Factor G then activates the clotting enzyme, which proceeds to activate coagulin. Limulus clotting enzyme is inhibited by serpins LICI-2 and LICI-3. These serpins regulate the coagulation cascade by preventing diffusion of active clotting factors, which could lead to unnecessary clot formation. The horseshoe crab coagulation cascade is an important defense mechanism against bacterial and fungal invaders. Clots contain and immobilize infectious cells, which can then be killed with antimicrobial substances produced by the hemocytes. This specialized system is useful because invertebrates lack adaptive immunity.
Sources: en.wikipedia.org
Russians, Belarusians, and Ukrainians, who were all East Slavic and Orthodox, shared close cultural, ethnic, and religious ties, while other groups did not. With multiple nationalities living in the same territory, ethnic antagonisms developed over the years. Members of various ethnicities participated in legislative bodies. Organs of power like the Politburo, the Secretariat of the Central Committee etc., were formally ethnically neutral, but in reality, ethnic Russians were overrepresented, although there were also non-Russian leaders in the Soviet leadership, such as Joseph Stalin, Grigory Zinoviev, Nikolai Podgorny, or Andrei Gromyko. During the Soviet era, a significant number of ethnic Russians and Ukrainians migrated to other Soviet republics, and many of them settled there. According to the last census in 1989, the Russian 'diaspora' in the Soviet republics had reached 25 million.
In the face of energetic German attempts to Nazify the international body, Jung resigned from its presidency in 1939, the year the Second World War started. Scholar Yosef Hayim Yerushalmi believed that Jung's antisemitism may have contributed to the schism between Freud and his circle of psychoanalysts, who were predominantly Jews. Jung is known to have possessed an interest in the Jewish mystic tradition of Kabbalah. and his interest in European mythology and folk psychology was shared by the Nazis. Richard Noll describes Jung's own reaction to this connection:
electron transport in the mitochondrial ETC, by shuttling electrons from mitochondrial complexes like nicotinamide adenine dinucleotide (NADH), ubiquinone reductase (complex I), and succinate ubiquinone reductase (complex II), the fatty acids and branched-chain amino acids oxidation (through flavin-linked dehydrogenases) to ubiquinol–cytochrome-c reductase (complex III) of the ETC: CoQ10 participates in fatty acid and glucose metabolism by transferring electrons generated from the reduction of fatty acids and glucose to electron acceptors; antioxidant activity as a lipid-soluble antioxidant together with vitamin E, scavenging reactive oxygen species and protecting cells against oxidative stress, inhibiting the oxidation of proteins, DNA, and use of vitamin E.
== Pharmacokinetics == Biotransformation is mainly hepatic, with approximately 30-40% metabolized to inactive metabolites. Protein Binding ranges from 60 to 80%. Cinoxacin is rapidly absorbed after oral administration. The presence of food delays absorption but does not affect total absorption. The mean serum half-life is 1.5 hours. Half-life in patients with impaired renal function may exceed 10 hours.
=== Treatment === Consumption of the death cap is a medical emergency requiring hospitalization. The four main categories of therapy for poisoning are preliminary medical care, supportive measures, specific treatments, and liver transplantation. Preliminary care consists of gastric decontamination with either activated carbon or gastric lavage; due to the delay between ingestion and the first symptoms of poisoning, it is common for patients to arrive for treatment many hours after ingestion, potentially reducing the efficacy of these interventions. Supportive measures are directed towards treating the dehydration which results from fluid loss during the gastrointestinal phase of intoxication and correction of metabolic acidosis, hypoglycemia, electrolyte imbalances, and impaired coagulation. No definitive antidote is available, but some specific treatments have been shown to improve survivability. High-dose continuous intravenous penicillin G has been reported to be of benefit, though the exact mechanism is unknown, and trials with cephalosporins show promise. Some evidence indicates intravenous silibinin, an extract from the blessed milk thistle (Silybum marianum), may be beneficial in reducing the effects of death cap poisoning. A long-term clinical trial of intravenous silibinin began in the US in 2010. Silibinin prevents the uptake of amatoxins by liver cells, thereby protecting undamaged liver tissue; it also stimulates DNA-dependent RNA polymerases, leading to an increase in RNA synthesis.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.